Lithuania, April 14th, 2026 – Ligence announces it has received its second U.S. Food and Drug Administration (FDA) 510(k) clearance for the newest iteration of its AI-powered echocardiography software, Ligence Heart. Building on its initial clearance, the updated platform now features fully automated Left Ventricular Global Longitudinal Strain (LV GLS) analysis and expanded deployment options, including private cloud integration.
While standard echocardiography measurements provide vital information, advanced metrics like LV GLS are increasingly critical for detecting myocardial dysfunction early. However, strain analysis is traditionally a complex, time-intensive process that requires meticulous manual contouring.
With this latest clearance, Ligence Heart automates this heavy lifting. Using advanced machine learning, the software automatically identifies standard echocardiographic views, detects the cardiac cycle and anatomical borders, and conducts precise contour tracking to generate LV GLS and segmental strain measurements.